Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC
Shanghai Simnova Biotech Co., Ltd. announced that its self‑developed anti‑DLL3 chimeric antigen receptor T‑cell (CAR‑T)...
Shanghai Simnova Biotech Co., Ltd. announced that its self‑developed anti‑DLL3 chimeric antigen receptor T‑cell (CAR‑T)...
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...
Galapagos NV (FRA: GXE) today disclosed that it has decided to wind down its cell‑therapy...
CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...
Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite,...
HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...
Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...
Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19‑targeted chimeric antigen receptor gene‑modified natural...
Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A—the world’s first B7H3‑targeted, off‑the‑shelf allogeneic...
Beijing RM Bio‑Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the...
In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA)...
Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...
China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...
On September 2, 2025, Shanghai‑based Regenelead announced that its internally developed cell‑therapy product RGL‑305 Injection received...
US-based Gilead Sciences’ (NASDAQ: GILD) subsidiary Kite Pharma has officially ended its $2.3 billion collaboration with Shoreline...
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
Suzhou HemaCell Therapeutics, a platelet‑regeneration‑focused cell‑therapy developer, announced that the Center for Drug Evaluation (CDE)...
China‑based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for...